Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 446

1.

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.

Antinori A, Meraviglia P, Monforte Ad, Castagna A, Mussini C, Bini T, Gianotti N, Rusconi S, Colella E, Airoldi G, Mancusi D, Termini R.

Drug Des Devel Ther. 2016 May 6;10:1589-603. doi: 10.2147/DDDT.S104875. eCollection 2016.

2.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015.

Antinori A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Di Biagio A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A.

New Microbiol. 2016 Feb;39(2):93-109. No abstract available.

3.

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.

Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Borderi M, Gibellini D, Caramatti G, Lazzarin A, Castagna A; MODAt Study Group.

J Antimicrob Chemother. 2016 Jun;71(6):1637-42. doi: 10.1093/jac/dkw031. Epub 2016 Mar 5.

PMID:
26945711
4.

Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.

Marcellusi A, Viti R, Russo S, Andreoni M, Antinori A, Mennini FS.

Clin Drug Investig. 2016 May;36(5):377-87. doi: 10.1007/s40261-016-0382-2.

PMID:
26940802
5.

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.

Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Castagna A, Antinori A, dʼArminio Monforte A; ICONA Foundation Study Group.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):263-71. doi: 10.1097/QAI.0000000000000849.

6.

Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.

Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill MJ, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, Del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, Monforte AD, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA; Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the HIV-CAUSAL Collaboration.

Int J Epidemiol. 2015 Dec 31. pii: dyv295. [Epub ahead of print]

PMID:
26721599
7.

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.

van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, Rachlis A, Bloch M, Segal-Maurer S, Garner W, Porter D, Bosse M, Piontkowsky D, Chuck SK, De-Oertel S.

AIDS. 2016 Jan;30(2):251-9. doi: 10.1097/QAD.0000000000000911.

PMID:
26684822
8.

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.

Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group.

PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015.

9.

Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.

Late presenters working group in COHERE in EuroCoord, Mocroft A, Lundgren J, Antinori A, Monforte Ad, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D, De Wit S, Fätkenheuer G, Furrer H, Jadand C, Johnson A, Lazanas M, Leport C, Moreno S, Mussini C, Obel N, Post F, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Loano I, Torti C, Warszawski J, Wittkop L, Zangerle R, Chene G, Raben D, Kirk O.

Euro Surveill. 2015;20(47). doi: 10.2807/1560-7917.ES.2015.20.47.30070.

PMID:
26624933
10.

Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.

Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L; NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group; NEAT 001/Agence Nationale de Recherche sur le SIDA ANRS 143 Study Group.

HIV Med. 2015 Nov 26. doi: 10.1111/hiv.12344. [Epub ahead of print]

PMID:
26611175
11.

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.

van Lunzen J, Pozniak A, Gatell JM, Antinori A, Klauck I, Serrano O, Baakili A, Osiyemi O, Sevinsky H, Girard PM.

J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):538-43. doi: 10.1097/QAI.0000000000000904.

12.

An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project.

Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A.

New Microbiol. 2015 Oct;38(4):443-90. Review.

13.

Adherence of hiv patients switching to emtricitabina+tenofovir disoproxil+rilpivirin. Real world evidence from italian administrative databases.

Degli Esposti L, Sangiorgi D, Buda S, Crovato E, Maggiolo F, Antinori A, Angarano G, Lazzarin A.

Value Health. 2015 Nov;18(7):A594. doi: 10.1016/j.jval.2015.09.1539. Epub 2015 Oct 20. No abstract available.

PMID:
26533337
14.

Topic: Incisional Hernia - The "risky" zone: sovrapubic, subxifoid, sub costal.

Tomaiuolo P, Mazzari A, Antinori A, Crucitti A, Berta R, Bellini R, Mancini R, Moretto C, Anselmino M, O'Hare L, Anwar S.

Hernia. 2015 Apr;19 Suppl 1:S356-7. doi: 10.1007/BF03355392. No abstract available.

PMID:
26518847
15.

European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements.

Mussini C, Antinori A, Bhagani S, Branco T, Brostrom M, Dedes N, Bereczky T, Girardi E, Gökengin D, Horban A, Lacombe K, Lundgren JD, Mendao L, Mocroft A, Oprea C, Porter K, Podlekareva D, Battegay M, d'Arminio Monforte A; European Aids Clinical Society.

HIV Med. 2015 Oct 22. doi: 10.1111/hiv.12347. [Epub ahead of print]

PMID:
26492497
16.

Discrepancies between physician's perception of depression in HIV patients and self-reported CES-D-20 assessment: the DHIVA study.

Marando F, Gualberti G, Costanzo AM, di Luzio Paparatti U, Franzetti M, Ammassari A, Antinori A, Galli M.

AIDS Care. 2016;28(2):147-59. doi: 10.1080/09540121.2015.1080794. Epub 2015 Oct 13.

17.

CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.

Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, Lichtner M, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group.

Lancet HIV. 2015 Mar;2(3):e98-106. doi: 10.1016/S2352-3018(15)00006-5. Epub 2015 Feb 6.

PMID:
26424550
18.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014.

Antinori A, Marcotullio S, Andreoni M, Ammassari A, d'Arminio Monforte A, Galli M, Girardi E, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group.

New Microbiol. 2015 Jul;38(3):299-328. No abstract available.

19.

stARTing cART now! HIV treatment Italian Guidelines Update Dec. 2014.

Lazzarin A, Antinori A, Marcotullio S.

New Microbiol. 2015 Jul;38(3):297-8. No abstract available.

20.

Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.

Fabbiani M, Zaccarelli M, Latini A, Sterrantino G, D'Ettorre G, Grima P, Mondi A, Rossetti B, Borchi B, Giuliani M, Antinori A, De Luca A, Di Giambenedetto S.

HIV Med. 2016 May;17(5):385-9. doi: 10.1111/hiv.12313. Epub 2015 Sep 22.

PMID:
26394902
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk